文献速递淋巴瘤

阿基仑赛桥接治疗大B细胞淋巴瘤:美国淋巴瘤CAR-T联盟结果

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.
PubMed 文献 · Blood Adv · 2024-01-01

研究基于美国多中心淋巴瘤CAR-T联盟数据,分析桥接治疗对复发/难治性大B细胞淋巴瘤患者接受阿基仑赛疗效的影响。中位随访33个月,298例白细胞单采患者中275例接受阿基仑赛。倾向性评分匹配后,桥接组与未桥接组在总缓解率、完全缓解率、无进展生存和总生存上均无统计学显著差异;放射桥接与非放射桥接结果相似。

要点

  • 桥接治疗组基线风险更高,倾向性评分匹配后两组疗效无统计学显著差异。
  • 匹配后总缓解率77% vs 87%(P=0.13),完全缓解率58% vs 70%(P=0.1)。
  • 放射桥接与非放射桥接结局相似,作者认为桥接治疗可能安全且不影响长期生存。

核心结论

  • 作者认为,对于制造期间需要疾病稳定的患者,桥接治疗可能安全且对长期生存无显著影响。
  • 作者认为,放射桥接相比非放射桥接没有明确优势。

研究设计与样本

  • 多中心美国淋巴瘤CAR-T联盟数据分析,中位随访33个月(范围4.3-42.1)。
  • 298例患者接受白细胞单采,其中275例接受阿基仑赛输注。
  • 52%的患者(n=143)接受桥接治疗,其基线风险特征高于未接受桥接治疗的患者。

主要发现

  • 桥接治疗组整体结局劣于未桥接组,但倾向性评分匹配后无统计学显著差异。
  • 匹配后桥接组 vs 未桥接组:总缓解率77% vs 87%(P=0.13),完全缓解率58% vs 70%(P=0.1)。
  • 匹配后桥接组 vs 未桥接组:无进展生存HR 1.25(P=0.23),总生存HR 1.39(P=0.09)。
  • 对全部白细胞单采患者进行意向性治疗分析,结果相似。
  • 放射桥接与非放射桥接的结局相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During the manufacturing period of autologous chimeric antigen receptor (CAR) T-cell therapy, patients may experience a decline in their condition due to cancer progression. In this study, we investigated the impact of bridging therapy (BT) on the outcome of patients with relapsed/refractory large B-cell lymphoma who received antilymphoma treatment between leukapheresis and axicabtagene ciloleucel (axi-cel) infusion. We conducted our analysis using data from the multicenter US Lymphoma CAR-T Consortium, with a median follow-up of 33 months (range, 4.3-42.1). Out of the 298 patients who underwent leukapheresis, 275 patients received axi-cel. A total 52% of patients (n = 143) who received BT had a higher baseline risk profile than patients who did not receive BT, and these patients, as a group, had inferior outcomes compared with those who did not receive BT. However, after propensity score matching between the 2 groups, there were no statistically significant differences in overall response rate (77% vs 87%; P = .13), complete response rate (58% vs 70%; P = .1), progression-free survival (hazard ratio [HR], 1.25; P = .23), and overall survival (HR, 1.39; P=.09) between the BT group and the no-BT group, respectively. Analyzing the effects of BT in the whole cohort that underwent leukapheresis regardless of receiving axi-cel (intention-to-treat analysis) showed similar results. Radiation BT resulted in outcomes similar to those observed with nonradiation BT. Our findings suggest that BT may be safe without a significant impact on long-term survival for patients who require disease stabilization during the manufacturing period. Moreover, our results suggest that there is no clear advantage to using radiation-based BT over nonradiation-based BT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jain MD, Jacobs MT, Gao F, et al. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024. PMID: 38051550. doi:10.1182/bloodadvances.2023011489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。